June 22, 2022 Life Science Tools M&A, Partnerships

Illumina Launches Research Test Codeveloped with Merck to Unlock Deeper Insights into the Tumor Genome

Jun 22, 2022 New assay brings  validated HRD technology from Myriad Genetics to the Illumina TruSight™ Oncology 500, a single, comprehensive pan-cancer test to identify key variants critical for cancer development and progression SAN DIEGO, June 22, 2022 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN), a global leader in DNA sequencing and array-based technologies, today announced the launch of a research... Read more

September 7, 2021 Clinical Research/Diagn. M&A, Partnerships

Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations

Sep 7, 2021 SAN DIEGO, Sept. 7, 2021 /PRNewswire/ — Illumina, Inc. (NASDAQ: ILMN) and Merck (known as MSD outside the United States and Canada) today announced a partnership to develop and commercialize tests that identify genetic mutations used in the assessment of homologous recombination deficiency (HRD). Patients whose tumors are HRD-positive may be eligible for... Read more

November 6, 2019 M&A, Partnerships

Promega Enters Global Collaboration with Merck to Develop Microsatellite Instability (MSI) Companion Diagnostic for Use with KEYTRUDA®

Madison, WI USA. (November 6, 2019) Promega Corporation today announced it has entered into a global collaboration with Merck, known as MSD outside the United States and Canada, to develop Promega’s microsatellite instability (MSI) technology as an on-label, solid tumor companion diagnostic (CDx) for use with Merck’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab). The global collaboration will initially... Read more

January 14, 2019 Bio/Pharma/CRO M&A, Partnerships

Merck and Roche Renew Global Distribution Agreement

DISTRIBUTION AGREEMENT ANNOUNCEMENT January 14, 2019 Merck and Roche Renew Global Distribution Agreement Global distribution agreement renewed under existing terms for additional five years Includes Biochemical Reagents and Kapa Biosystems portfolios, and select qPCR & Nucleic Acid Purification products Merck and Roche have agreed to renew their current distribution agreement for the Biochemical Reagents and... Read more

September 17, 2018 Bio/Pharma/CRO Informatics & Software M&A, Partnerships

Accenture and Merck Collaborate with Amazon Web Services to Launch a Research Platform to Drive Innovation in Drug Discovery and Scientific Research

NEW YORK; Sept. 17, 2018 – Accenture and Merck, known as MSD outside the United States and Canada, in collaboration with Amazon Web Services (AWS), will launch a cloud-based informatics research platform designed to help organizations in the life sciences industry improve productivity, efficiency and innovation in the early stages of drug development. The new research platform,... Read more

April 17, 2018 Bio/Pharma/CRO M&A, Partnerships Mass Spectrometry

Labcyte Reaches Agreement With Merck to Supply Acoustic-Mass Spectrometry Equipment

April 17, 2018 04:30 AM Pacific Daylight Time SAN JOSE, Calif.–(BUSINESS WIRE)–Labcyte Inc. announced today that the company has entered an agreement with Merck, known as MSD outside the United States and Canada, to utilize Acoustic-Mass Spectrometry (Acoustic-MS) in drug discovery and development. Pioneered by Labcyte, acoustic droplet ejection (ADE) technology uses the gentle energy... Read more